BioSpace News Archive

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-line results from Cohort 2 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD).

Thrive to analyze more than five years of Blue Cross and Blue Shield claims to detect cancer earlier and more cost-effectively

Michael J. Biercuk, founder and CEO of Q-CTRL, will describe how quantum sensors may provide exceptional new capabilities to the warfighter at the Office of Naval Research (ONR) on Jan. 13, 2020, as part of the ONR’s 2020 Distinguished Lecture Series.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) in development for the treatment of primary hyperoxaluria type 1 (PH1), met its primary efficacy endpoint and all tested secondary endpoints

ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI)

Bausch Health Companies Inc. announced that it has launched an offering of a combined $1,250,000,000 aggregate principal amount of new senior notes due 2028 and new senior notes due 2030.

Onconova Therapeutics, Inc. (NASDAQ:ONTX), , and Pint Pharma, today announced the receipt of approval from the Brazilian Health authority to initiate the INSPIRE Trial in Brazil with intravenous rigosertib in Higher-Risk MDS (HR-MDS).

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it has completed patient enrollment in the REST-ON Phase 3 clinical trial for FT218.

Mr. Heffernan was most recently CEO of Collegium Pharmaceutical, a publicly traded pharmaceutical company that he founded and that is focused on developing and commercializing products for the treatment of chronic pain and related disorders.

Hitchman Brings Deep Experience in Product Development, Commercialization and Operations